Published on : Dec 19, 2017
Albany, New York, December 19, 2017: According to a new research titled “Small Molecule API Market: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027”, the global market is likely to grow at a CAGR of nearly 5% through 2027. The report has offers forecast and analysis for a ten year period, and has been added to the vast repository of Market Research Hub (MRH).
According to the report, the growth of small molecule API market is influenced by a range of macroeconomic and microeconomic factors. Healthcare spending, combined with focus on developing advanced pharmaceuticals continue to provide growth opportunities to companies in the small molecule API market. Outsourcing of APIs from India and China continue to be a prevailing trend in the market, owing to which Asia Pacific excluding Japan (APEJ) is one of the leading markets globally. Easy availability of raw materials, combined with cheap labor costs have made APEJ an attractive destination for API companies. Further, favorable government legislations and lax regulation policy are also supporting the industry in the APEJ. According to the report, the APEJ small molecule API market is likely to grow at a CAGR of 5.8% during the forecast period 2017-2027. The APEJ market held a revenue share of nearly 34% of the market, and the revenue share is likely to increase during the assessment period.
The report offers detailed segment-wise analysis to give detailed insights and analysis to readers. On the basis of molecule type, the market has been segmented into standard API and high potency API. By production, the market has been segmented into in-house and outsourced. Clinical and commercial are the key application segments of the small molecule API market. By therapeutic area, the key segments include cardiovascular, infectious, oncology, respiratory, immunology, dermatology, ophthalmology, neurology, and general health.
According to the report, high potency API is likely to grow at a higher CAGR as compared to standard API; however, in terms of revenue share, standard API still continues to dominate. By therapeutic area, oncology segment is likely to grow at a higher CAGR during the assessment period, whereas outsourced production method will continue to grow at a robust pace. Commercial segment remains the dominant segment in terms of revenues and is likely to remain so during the forecast period.
Some of the leading companies profiled in the report include GlaxoSmithKline PLC, Novartis AG, PCAS, Johnson Matthey, Siegfried Holding AG, Sanofi S.A, Pfizer, Bristol-Myers Squibb, BASF SE, Catalent Inc., Patheon N.V, Albany Molecular Research Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Bachem Holding AG, Cambrex Corporation AstraZeneca, Johnson & Johnson, Teva Pharmaceuticals, F. Hoffman-La Roche Ltd., and Gilead Sciences Inc.
Request a Sample with TOC in a PDF format :
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org